Clinical Trial Update: Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1 [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating Trabedersen (OT-101) in combination with pembrolizumab for newly diagnosed advanced Non-small cell lung cancer with positive PD-L1 is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Trabedersen (OT-101)

Snippet

Sponsor: University of Nebraska | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING